Three Months

Alto Ingredients, Inc. Reports Fourth Quarter and Year-end 2023 Results

Retrieved on: 
Monday, March 11, 2024

PEKIN, Ill., March 11, 2024 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a producer and distributor of renewable fuel and essential ingredients and the largest producer of specialty alcohols in the U.S., reported its financial results for the quarter and year ended December 31, 2023. For the fourth quarter of 2023, gross loss improved $18.8 million and Adjusted EBITDA improved $19.0 million over the fourth quarter of 2022. For the full year 2023, gross profit improved $43.2 million and Adjusted EBITDA improved $26.5 million over 2022.

Key Points: 
  • For the fourth quarter of 2023, gross loss improved $18.8 million and Adjusted EBITDA improved $19.0 million over the fourth quarter of 2022.
  • For the full year 2023, gross profit improved $43.2 million and Adjusted EBITDA improved $26.5 million over 2022.
  • Financial Results for the Three Months Ended December 31, 2023 Compared to 2022
    Net sales were $273.6 million, compared to $328.4 million.
  • Financial Results for the Year Ended December 31, 2023 Compared to 2022
    Net sales were $1,222.9 million, compared to $1,335.6 million.

Aemetis Reports 2023 Fourth Quarter and Year-End Results

Retrieved on: 
Thursday, March 7, 2024

CUPERTINO, CA, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products, today announced its financial results for the fourth quarter and twelve months ended December 31, 2023.

Key Points: 
  • “Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022.
  • Financial Results for the Three Months Ended December 31, 2023
    Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022.
  • The ethanol gallons sold increased from 13.4 million gallons during the fourth quarter of 2022 to 15 million gallons during the fourth quarter of 2023.
  • Selling, general and administrative expenses rose from $7.5 million during the fourth quarter of 2022 to $9.8 million during the fourth quarter of 2023.

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, March 6, 2024

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate developments.

Key Points: 
  • “With important data readouts expected from our two lead programs, 2024 has the potential to be a transformational year for PepGen.
  • People with myotonic dystrophy type 1 (DM1) currently have no approved treatment options that target the root cause of the disease.
  • Financial Results for the Three Months and Twelve Months ended December 31, 2023
    Cash and cash equivalents were $110.4 million as of December 31, 2023.
  • Net loss was $78.6 million for the year ended December 31, 2023, compared to $69.1 million for the same period in 2022.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

Pactiv Evergreen Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) today reported results for the fourth quarter of 2023. Michael King, President and Chief Executive Officer of Pactiv Evergreen, said, “This was a pivotal year for Pactiv Evergreen. The Company’s commitment to operational excellence and profitable growth helped offset the headwinds we encountered throughout the year. Our teams demonstrated agility and discipline, allowing the Company to exceed its financial goals while also delivering for customers. The Company made significant progress on multiple fronts of its transformational journey in 2023, and I cannot thank our employees enough for their hard work. Looking ahead to 2024, the Company plans to initiate the next phase of its strategic transformation through a footprint optimization plan, which will include the rationalization of a portion of the Company’s production capacity. We expect these actions to generate significant annual cost savings and better align resources and capabilities with customers’ needs as the Company targets sustainable growth opportunities.”

Key Points: 
  • Fourth Quarter 2023 Financial Highlights:
    Total Net Revenues of $1,274 million for the fourth quarter of 2023 were down 14% compared to $1,476 million in the fourth quarter of 2022 and down 8% compared to $1,379 million in the third quarter of 2023.
  • Adjusted EPS1 of $0.33 for the fourth quarter of 2023 compared to $0.17 in the fourth quarter of 2022 and $0.32 in the third quarter of 2023.
  • LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) today reported results for the fourth quarter of 2023.
  • Fourth Quarter 2023 Results vs. Fourth Quarter 2022 Results
    Total net revenues in the fourth quarter of 2023 were $1,274 million compared to $1,476 million in the fourth quarter of 2022.

PropertyGuru Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Friday, March 1, 2024

PropertyGuru Group Limited (NYSE: PGRU) (“PropertyGuru” or the “Company”), Southeast Asia’s leading1, property technology (“PropTech”) company, today announced financial results for the quarter ended December 31, 2023.

Key Points: 
  • PropertyGuru Group Limited (NYSE: PGRU) (“PropertyGuru” or the “Company”), Southeast Asia’s leading1, property technology (“PropTech”) company, today announced financial results for the quarter ended December 31, 2023.
  • Revenue of S$42 million in the fourth quarter 2023 increased 4% year over year.
  • Net income in the fourth quarter of 2023 was S$1 million, a distinct improvement over a loss of S$5 million in the fourth quarter of 2022, and the second sequential quarter in a row of positive net income.
  • The number of listings was 1.2 million in the fourth quarter down 26% from the fourth quarter of 2022.

Perfect Corp. Reports Unaudited Financial Results for the Three Months Ended December 31, 2023 and for the Full Year of 2023

Retrieved on: 
Wednesday, February 28, 2024

Full year net income was $5.4 million for 2023, compared to a net loss of $161.7 million for 2022.

Key Points: 
  • Full year net income was $5.4 million for 2023, compared to a net loss of $161.7 million for 2022.
  • Full year adjusted net income (non-IFRS) was $7.0 million for 2023, compared with $4.1 million for 2022, an increase of 72.1%.
  • Operating cash flow was positive $13.6 million in full year 2023, compared to negative $3.3 million in full year 2022.
  • The Company had 162 Key Customers as of December 31, 2023, compared with 169 Key Customers as of September 30, 2023.

Nuvei Announces Fourth Quarter and Fiscal 2023 Results

Retrieved on: 
Tuesday, March 5, 2024

MONTREAL, March 5, 2024 /PRNewswire/ -- Nuvei Corporation ("Nuvei" or the "Company") (Nasdaq: NVEI) (TSX: NVEI), the Canadian fintech company, today reported its financial results for the three months and year ended December 31, 2023. The Company's results are also included in a quarterly shareholder letter which can be found in the "Events and presentations" and "Financial information" sections of the Company's Investor Relations website at https://investors.nuvei.com

Key Points: 
  • MONTREAL, March 5, 2024 /PRNewswire/ -- Nuvei Corporation ("Nuvei" or the "Company") (Nasdaq: NVEI) (TSX: NVEI), the Canadian fintech company, today reported its financial results for the three months and year ended December 31, 2023.
  • B2B, government and ISV revenue increased 19% year over year on a pro forma basis(g), to $59 million and represented 18% of total revenue in the fourth quarter.
  • SMB revenue increased 2% year over year on a pro forma(g) basis, to $82 million and represented 26% of total revenue in the fourth quarter.
  • In summary, total revenue increased 11% year over year on a pro forma(g) basis in the fourth quarter.

KBR Announces Fourth Quarter and Fiscal 2023 Financial Results; Issues Fiscal 2024 Guidance

Retrieved on: 
Tuesday, February 20, 2024

HOUSTON, Feb. 20, 2024 /PRNewswire/ -- KBR, Inc. (NYSE: KBR) today announced its fourth quarter and fiscal 2023 financial results and issued its fiscal 2024 financial guidance.

Key Points: 
  • Adjusted EBITDA2 was $188 million, up 20% compared to 4Q'22, with Adjusted EBITDA2 margins of 10.9%, up 110 bps over 4Q'22.
  • Diluted earnings per share were in line with the decrease in Net income attributable to KBR.
  • Additionally, on February 19, 2024, the Board of Directors authorized replenishment of our share repurchase authorization to $500 million.
  • The table below summarizes FY24 guidance and represents our views as of February 20, 2024.

Casella Waste Systems, Inc. Announces Fourth Quarter and Fiscal Year 2023 Results and Provides Fiscal Year 2024 Guidance

Retrieved on: 
Thursday, February 15, 2024

The Company also provided guidance for the fiscal year ending December 31, 2024 ("fiscal year 2024").

Key Points: 
  • The Company also provided guidance for the fiscal year ending December 31, 2024 ("fiscal year 2024").
  • Revenues were $1.265 billion for the fiscal year ended December 31, 2023 ("fiscal year 2023"), up $179.5 million, or up 16.5%, from the fiscal year ended December 31, 2022 ("fiscal year 2022").
  • Net income was $25.4 million for fiscal year 2023, as compared to net income of $53.1 million in fiscal year 2022.
  • Adjusted EBITDA was $294.6 million for fiscal year 2023, up $49.4 million, or up 20.1%, from fiscal year 2022.